If You Invested in Biocardia (BCDAW)
Looking for the live price? See the BCDAW quote & overviewWhat $1,000 or $10,000 in BCDAW Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Aug 2, 2019 |
|---|---|---|---|---|
| $1,000 | — | $4 -100% | — | $6 -99% |
| $10,000 | — | $37 -100% | — | $61 -99% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for BCDAW$1,000 Investment Over Time
BCDAW vs S&P 500Year-by-Year Returns
BCDAW annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2019 | $1.00 | $1.04 | +4.0% | +4.0% |
| 2020 | $1.46 | $1.54 | +5.6% | +54.0% |
| 2021 | $1.54 | $1.11 | -27.9% | +11.0% |
| 2022 | $0.82 | $0.83 | +0.8% | -17.3% |
| 2023 | $0.84 | $0.01 | -98.5% | -98.8% |
| 2024 | $0.02 | $0.01 | -61.9% | -99.4% |
About Biocardia
Biological Products, (no Disgnostic Substances) · NASDAQ
BioCardia, Inc. (associated with the trading symbol BCDAW) is described in its public disclosures as a clinical-stage regenerative medicine company focused on developing novel therapeutics for cardiovascular diseases with large unmet medical needs. According to available information, BioCardia is involved in cellular and cell-directed therapeutics that target cardiovascular and pulmonary diseases, and it develops proprietary biotherapeutic solutions and delivery systems to support these therapies.
The company has stated that it is developing comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP and Cardiallo therapies. Clinical results supporting these therapeutic programs are described as compelling and build upon rigorous data in the field related to intramyocardial delivery of marrow-derived cells. These programs are enabled by BioCardia’s Helix transendocardial delivery systems and Morph vascular access products, which are also partnered to support other biotherapeutic programs.
Business focus and technology
BioCardia’s disclosures characterize it as a global leader in cellular and cell-directed therapeutics for the treatment of cardiovascular and pulmonary diseases. Its work includes the development of the CardiAMP Cell Therapy System, which is referenced in regulatory and clinical contexts, and the Helix Transendocardial Delivery Catheter. These technologies are used in connection with intramyocardial delivery of cell-based therapies and are part of the company’s approach to treating heart failure and related cardiovascular conditions.
The company has reported activities related to regulatory pathways for its CardiAMP Cell Therapy System, including seeking approvals from the U.S. Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). It has also described a pivotal Phase 3 CardiAMP HF II trial enrolling patients with ischemic heart failure, indicating that its therapeutic programs are being evaluated in advanced-stage clinical studies.
Partnerships and imaging platform
BioCardia has disclosed an exclusive development and commercialization agreement with CART-Tech B.V., a provider of vendor independent platform technology for augmented fluoroscopy during cardiac interventions. Under this agreement, the parties are working on Heart3D Fusion Imaging. The Heart3D system is expected to enhance two-dimensional x-ray images used for cardiac biotherapeutic delivery and biopsy procedures by fusing them with annotated pre-procedure three-dimensional anatomical heart models created from MRI and CT imaging. This collaboration is intended to support more precise delivery and assessment of cardiac biotherapeutic procedures.
Intellectual property and delivery systems
In its regulatory filings, BioCardia has reported that the United States Patent Office granted a patent titled “Radial and Trans-endocardial Delivery Catheter.” This patent relates to catheter technology that is consistent with the company’s focus on transendocardial delivery systems for cardiovascular therapies. The Helix transendocardial delivery systems and Morph vascular access products are core enabling technologies for the company’s cell therapy programs and for other partnered biotherapeutic initiatives.
Regulatory and capital markets activity
BioCardia has reported multiple material events through current reports on Form 8-K. These include press releases on clinical trial enrollment, regulatory consultations, and anticipated timing of regulatory activities for its CardiAMP Cell Therapy System and Helix Transendocardial Delivery Catheter. The company has also disclosed private placement transactions involving shares of common stock and warrants, entered into with qualified institutional buyers, institutional accredited investors, and certain members of its board of directors and executive officers. The proceeds from such private placements have been described as intended for general corporate purposes.
The company’s filings reference the use of registration statements with the U.S. Securities and Exchange Commission to provide for the resale of shares and issuable shares underlying warrants, and they describe reliance on exemptions from registration under the Securities Act of 1933 for certain private offerings. These disclosures reflect BioCardia’s use of capital markets to support its ongoing clinical and development activities.
Clinical and geographic context
BioCardia has reported that its CardiAMP autologous cell therapy investigational heart failure treatment has been submitted for clinical consultation with Japan’s PMDA, highlighting Japan as an important market for advanced heart failure therapies in the company’s planning. It has also announced that a major health institution in Detroit, Michigan is enrolling patients with ischemic heart failure in the pivotal Phase 3 CardiAMP HF II trial, underscoring the clinical-stage nature of its programs and their evaluation in real-world healthcare settings.
The company’s principal executive offices are located in Sunnyvale, California, reflecting its base within a major U.S. hub for medical technology and life sciences companies. This location aligns with its focus on medical devices, delivery systems, and regenerative medicine technologies for cardiovascular and pulmonary diseases.
Role of BCDAW
The symbol BCDAW is associated with BioCardia in the context of the company’s securities, including warrants referenced in its SEC filings. Investors researching BCDAW are typically looking at securities linked to BioCardia’s broader business in clinical-stage regenerative medicine, cardiovascular cell therapies, and related delivery technologies. Understanding the underlying company, its therapeutic programs, and its regulatory and clinical milestones can be important when evaluating instruments tied to this symbol.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Biocardia investment returns
How much would $1,000 invested in Biocardia be worth today?
If you invested $1,000 in Biocardia (BCDAW) 5 years ago on 2021-07-06, your investment would be worth $4 today, representing a -99.6% total return, growing at a compounded rate of -83.8% per year (CAGR).
Has Biocardia outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare BCDAW performance over available time periods.
What is Biocardia's average annual return?
The compound annual growth rate (CAGR) of BCDAW over the past 5 years is -83.8%, growing at a compounded rate each year. Individual years vary significantly — BCDAW's best recent year was 2020 (+5.6%) and worst was 2023 (-98.5%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
